首页> 外文期刊>International journal of molecular medicine >Efficient delivery of HBV NLS siRNAs into HepG2.2.15 cells for HBV inhibition through novel recombinant preS1-tP proteins
【24h】

Efficient delivery of HBV NLS siRNAs into HepG2.2.15 cells for HBV inhibition through novel recombinant preS1-tP proteins

机译:通过新型重组PRE1-TP蛋白将HBV NLS SIRNA的HBV NLS SIRNA的高效递送进入HEPG2.2.15细胞

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatitis B virus (HBV) infection and related liver complications remain severe public health problems worldwide. Previous investigations have shown that small interfering (si)RNAs can offer an effective strategy for the treatment of chronic hepatitis B. The present study aimed to develop a novel siRNA-delivering system of therapeutic HBV nuclear localization sequence (NLS) siRNAs using the recombinant preS1-truncated protamine (tP) proteins. The preS1 region of the LHB was used in place of scFv to construct the recombinant preS1-tP proteins, which were applied to deliver siRNAs targeting the HBV NLS to inhibit HBV replication and infection in HepG2.2.15 cells overexpressing sodium taurocholate cotransporting polypeptide (NTCP). The results revealed that HepG2.2.15 cells with stable NTCP expression (HepG2.2.15-NTCP cells) transfected with the recombinant lentivirus showed increased expression of NTCP genes. The HBV NLS siRNAs significantly suppressed HBV mRNA content and levels of HBsAg and HBeAg in the HepG2.2.15-NTCP cells. Recombinant preS1-tP proteins tagged with His and glutathione S-transferase were found to enter into HepG2.2.15-NTCP cells and bind with DNA. The HBV NLS siRNAs were delivered into HepG2.2.15-NTCP cells by recombinant preS1-tP proteins, which resulted in decreased expression of HBV mRNA, HBsAg and HBeAg, HBV DNA and covalently closed circular DNA in the HepG2.2.15-NTCP cells. Therefore, the recombinant preS1-tP proteins successfully delivered NLS siRNAs into HepG2.2.15 cells and repressed HBV infection and replication.
机译:乙型肝炎病毒(HBV)感染和相关肝脏并发症仍然是全世界严重的公共卫生问题。先前的研究表明,小干扰(Si)RNA可以提供治疗慢性乙型肝炎的有效策略。目前的研究旨在使用重组PRE1开发治疗性HBV核定位序列(NLS)SIRNA的新型siRNA输送系统 - 截断的protamine(TP)蛋白。使用LHB的PRE1区域代替SCFV以构建重组PRE1-TP蛋白,其施用靶向HBV NLS的SIRNA,以抑制HBG2.2.15细胞中的HBV复制和感染过表达牛磺酸钠CotroAntporting多肽(NTCP) 。结果表明,用重组慢病毒转染的具有稳定NTCP表达(HepG2.2.15-NTCP细胞)的HepG2.2.15细胞显示出NTCP基因的表达增加。 HBV NLS SIRNA在HepG2.2.15-NTCP细胞中显着抑制HBV mRNA含量和HBsAg和HBeAg水平。发现标有他和谷胱甘肽S转移酶的重组PRE1-TP蛋白被发现进入HepG2.2.15-NTCP细胞并与DNA结合。通过重组PRE1-TP蛋白将HBV NLS SIRNA送入HepG2.2.15-NTCP细胞中,导致HPG2.2.15-NTCP细胞中的HBV mRNA,HBSAG和HBEAG,HBV DNA和共价闭合的圆形DNA表达下降。因此,重组PRE1-TP蛋白成功地将NLS SIRNA递送至HepG2.2.15细胞并抑制HBV感染和复制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号